We are live on ! Find out more
OXFD

Oxford Immunotec Global PLC Ordinary Shares
OXFD

Delisted

OXFD was delisted on the 5th of March, 2021.

49 hedge funds and large institutions have $171M invested in Oxford Immunotec Global PLC Ordinary Shares in 2014 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

50% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 12

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

0% more funds holding

Funds holding: 4949 (0)

4% less capital invested

Capital invested by funds: $178M → $171M (-$7.07M)

Holders
49
Holders Change
Holders Change %
0%
% of All Funds
1.31%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
7
Increased
18
Reduced
12
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$542K -$14.3K -1,045 -3%
BIM
27
BlackRock Investment Management
Delaware
$514K +$1.83K +134 +0.4%
PC
28
Polar Capital
United Kingdom
$355K +$170K +12,403 +91%
PSC
29
Piper Sandler & Co
Minnesota
$354K +$355K +26,000 New
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$329K +$1.41K +103 +0.4%
Vanguard Group
31
Vanguard Group
Pennsylvania
$283K +$6.72K +492 +2%
Charles Schwab
32
Charles Schwab
California
$261K
TA
33
Teachers Advisors
New York
$252K
WCA
34
Whetstone Capital Advisors
Kansas
$218K
Geode Capital Management
35
Geode Capital Management
Massachusetts
$218K +$20.1K +1,472 +10%
CS
36
Credit Suisse
Switzerland
$155K +$156K +11,446 New
NFA
37
Nationwide Fund Advisors
Ohio
$136K +$1.83K +134 +1%
AIG
38
American International Group
New York
$111K -$4.4K -322 -4%
BA
39
BlackRock Advisors
Delaware
$69K -$5.03K -368 -7%
Citigroup
40
Citigroup
New York
$30K +$24.3K +1,779 +393%
Barclays
41
Barclays
United Kingdom
$10K +$4.29K +314 +74%
AllianceBernstein
42
AllianceBernstein
Tennessee
$8K
UBS Group
43
UBS Group
Switzerland
$8K +$7.6K +556 New
FI
44
Fosun International
China
$6.37K
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
$1K +$998 +73 New
TRCT
46
Tower Research Capital (TRC)
New York
$1K +$1.37K +100 New
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$77 -$46.1K -3,375 -37%
NCGI
48
Next Century Growth Investors
Minnesota
-$3.32M -217,455 Closed
MHP
49
Manatuck Hill Partners
Connecticut
-$763K -50,000 Closed
TC
50
TFS Capital
Pennsylvania
-$230K -15,065 Closed

OXFD Hedge Fund Activity: Q4 2014 in Review

49 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q4 2014, worth a combined $171M — down 4% from $178M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new OXFD positions and 6 closed out — a net gain of 1 holder — while 18 added to existing stakes and 12 trimmed.

The largest buyer was First Light Asset Management, adding an estimated $1.14M. The largest seller was Next Century Growth Investors, exiting entirely with an estimated $3.32M sold.

  • 49 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $171M of Oxford Immunotec Global PLC Ordinary Shares stock for Q4 2014, down 4% quarter-over-quarter.
  • 7 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q4 2014 and 6 closed out, a net change of +1 holder.
  • The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q4 2014 was First Light Asset Management, an estimated $1.14M added.
  • The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q4 2014 was Next Century Growth Investors, an estimated $3.32M sold.

Based on aggregated 13F filings for Q4 2014.